A-Portfolio

The company in one breath

Retension Pharmaceuticals, ticker RTSN on the Nasdaq Capital Market, is a clinical-stage drug developer with one asset and no revenue.

That asset, RTN-001, is a once-daily pill meant for people whose high blood pressure stays too high despite taking two or more medicines. It blocks PDE-5, an enzyme that weakens a natural signal that relaxes blood vessels. Good would look like RTN-001 lowering pressure all day on top of existing drugs, without adding serious safety trouble.

The crude nickname is “Viagra for blood pressure,” because both drugs block PDE-5. The real pitch is more specific. Retension says RTN-001 reaches the thick muscle around major arteries better than older PDE-5 drugs. Good would look like the ongoing trial proving that tissue targeting creates a useful blood-pressure drop, not merely a clever diagram.

Why now

The stock began trading on October 9 after an upsized initial public offering, the first sale of shares to the public. Retension sold 3.75 million shares at $12 each and raised $45 million before fees. That means public investors now fund the expensive clinical work. Good for a tiny biotech would look like enough cash to reach the next major data release without another stock sale, and Retension says this offering gets it there.

The next verdict comes from a 280-patient Phase 2b trial, a mid-stage study that tests whether the drug works, which dose works best, and whether side effects stay manageable. ClinicalTrials.gov now shows 34 sites, an estimated primary completion in March 2027, and full completion in June 2027. Good would look like enrollment finishing on time and initial results arriving in the first half of 2027, as management promises.

There is already a yellow flag. The estimated primary completion moved from October 2026 to March 2027. That means the timetable slipped by roughly five months. Good would look like no more movement and a precise data date before the cash clock starts yelling from the back seat.

The latest completed close was $11.63 on October 13, about 3.1% below the $12 offer price. That means the market has not crowned this thing after three trading days. Good entry quality would look like either a much cheaper pre-data price or strong data arriving before the stock demands payment for success.

The numbers, translated

• Revenue is $0. Retension has no approved drug to sell, so every dollar comes from investors rather than customers. Good would look like a partnership payment before approval, then product revenue only after regulators say yes.
• The first-half 2026 net loss was $7.5 million, up from $1.9 million one year earlier. Net loss is how much money the business lost after expenses, and this one nearly quadrupled as the trial grew. Good would look like spending rising because enrollment is accelerating, then flattening after the Phase 2b work finishes.
• Research spending was $6.2 million in the first half, up 427%. Research spending is the money going into the drug and its trial. Good would look like that cash buying completed patients, clean data, and a Phase 3 plan, not merely a larger invoice pile.
• Pro forma cash was about $52.6 million after the IPO. Pro forma means the company shows what the balance sheet would have looked like if the offering had already closed on June 30. That equals about $6.31 per current share before later spending. Good would look like at least $35 million still in the bank when Phase 2b data arrives.
• Management says the cash funds at least 21 months of operations. Runway is how long the bank account can carry the business at its planned spending rate. Good would look like reaching the data, meeting regulators, and starting Phase 3 preparation before the company asks shareholders for more money.
• Retension plans to spend about $18 million finishing Phase 2b and $10 million preparing Phase 3. That means the IPO funds the answer to the first big question, but not the whole trip to approval. Good would look like positive data attracting a deep-pocketed partner before a full Phase 3 bill lands on shareholders.
• The basic market value is about $96.9 million at $11.63. Market value is the price of all current shares. After subtracting the pro forma cash, investors pay roughly $44.3 million for the drug program itself. Good would look like that program value staying below $50 million before proof, or rising only after the trial earns it.
• Options, warrants, and the new employee-share reserve could add shares equal to about 31% of today’s share count. Those claims can make each current share own a smaller slice. Good would look like management using stock sparingly and avoiding a new financing before Phase 2b results.
• The old trials exposed 243 people to RTN-001 with no drug-related serious adverse events. That means the early safety file has substance. Good would look like the 280-patient study preserving that record while proving efficacy with the new modified-release pill.

What I like

The target is enormous and painfully real. About 120 million U.S. adults have hypertension, which means nearly half the adult population has high blood pressure. Good would look like Retension first winning a narrow group, people still uncontrolled on several medicines, rather than pretending it can replace every cheap generic in America.

A small blood-pressure move can matter. The prospectus says a reduction of 5 millimeters of mercury, the unit on a blood-pressure reading, can improve cardiovascular outcomes. Good would look like RTN-001 beating placebo by at least 5, then getting closer to 8 with a clean all-day reading. That would put it in the same conversation as serious add-on treatments, not the supplement aisle.

The mechanism is different from the crowded aldosterone field. AstraZeneca (AZN) has an approved aldosterone-synthesis drug, while other developers attack that same hormone pathway. RTN-001 boosts nitric-oxide signaling instead. Good would look like doctors using it alongside those drugs because it adds benefit through a different biological door.

The early safety record helps. Across nine completed trials and 243 treated participants, the common problems looked like known PDE-5 effects, including headache, flushing, and visual disturbance, with no drug-related serious event reported. Good would look like that familiarity shortening the argument over safety so efficacy can carry the day.

The offering itself was not a flop. Retension increased the deal from 3.3 million to 3.75 million shares and priced at the midpoint of the $11 to $13 range. That means buyers accepted more stock without demanding the bottom price. Good would look like the underwriters buying their extra allotment and the stock holding above the $12 offer as the trial approaches.

What worries me

The company will not disclose the actual blood-pressure reductions from its two pilot studies in the prospectus summary. It calls them “clinically meaningful,” then gives p-values, which tell you whether a result may be real, without giving the effect size, which tells you how big it was. Good would look like management publishing the missing millimeter figures and the full dose-by-dose data. Calling dinner delicious while hiding the plate is cute once.

The largest pilot had only 40 patients, used an immediate-release version, and lasted 14 days on drug after 14 days on placebo. The new trial uses a different modified-release formulation for 12 weeks. Good would look like all three new doses producing a sensible ladder, more drug creates more effect until the best dose appears, with the 24-hour monitor confirming the office cuff.

The competition already has better proof. A 2026 JACC: Advances analysis estimated that baxdrostat lowered office systolic pressure by 8.68 millimeters of mercury, while spironolactone, a cheap standard drug, lowered it by 12.43. Good would look like RTN-001 delivering at least 5 with cleaner monitoring or at least 8 with competitive tolerability. Different mechanism does not mean the scoreboard disappears.

The intellectual property is messy. The licensed composition-of-matter patent, the strongest kind because it covers the molecule, nominally expires in 2027. Retension owns a newer crystal-form patent that runs to at least 2044, but crystal patents can face workarounds and challenges. Good would look like additional patents covering formulation, dosing, and use, plus a clean legal opinion that Retension owns the economics.

The royalty can bite. The license requires a low-teens percentage of future sales or sublicensing revenue, and the filing says the newer crystal patent may also fall under those obligations. That means more than a dime from each future sales dollar could leave before Retension pays for manufacturing and selling. Good would look like a final agreement that caps the royalty and removes the ownership dispute.

Management brings history with the molecule, but history also brings baggage. The chief executive and chief scientific officer manage Redux Therapeutics, the related party that sublicensed the drug to Retension, and they may benefit from future royalties. The company also restated its 2025 accounts and admits a material weakness in financial controls. Good would look like independent directors resolving the patent and royalty questions, then an auditor reporting clean controls.

Public evidence is almost nonexistent. Thirty-day research found one relevant Reddit post with one upvote and one tiny YouTube video with 40 views. That means there is no useful crowd verdict from patients, clinicians, or specialist investors. Good would look like trial investigators discussing enrollment and outside experts debating the actual data. Silence is not bearish. It is just no help at all.

What would make this a buy

My position size is zero. This is research and commentary, never a buy signal.

I want the Phase 2b result first. The drug needs to beat placebo by at least 8 millimeters of mercury on office systolic pressure at four weeks, show a clean dose response across 15, 30, and 45 milligrams, and confirm at least a 5-millimeter benefit on the 24-hour monitor. Good would mean the pill works in the clinic, across the whole day, and for the dose Retension can carry into Phase 3.

Safety must stay boring. I want no drug-related serious adverse event, no troublesome fainting signal, and discontinuations close to placebo. Good would look like headache and flushing staying manageable while blood pressure falls for the right reason.

Then I want cash above $35 million, a detailed Phase 3 agreement with regulators, and either a partner or a financing plan that does not hammer existing owners. At a price of $13 or less after meeting those tests, the current share count would value the company near $108 million before future dilution. Good would look like the proven program still carrying a modest value compared with the cost and value of a credible late-stage hypertension drug.

Without data, I would only reopen the file near $9. At that price, the current shares would be worth about $75.0 million, leaving roughly $22.4 million above the stated post-IPO cash. That is a better price for a binary experiment, but cheap uncertainty is still uncertainty.

What makes me walk away

I walk if the placebo-adjusted office systolic reduction is below 5 millimeters of mercury. That would miss the minimum clinical bar the company itself uses to explain why small changes matter.

I walk if the doses behave randomly, the 24-hour monitor fails to confirm the office reading, or the March 2027 primary completion slips again. That would tell me the old pilot signal did not survive a larger, cleaner test or that execution cannot keep pace with the cash clock.

I walk if serious low-blood-pressure events, fainting, or visual problems force many patients off treatment. A chronic drug has to be tolerable every day. A medicine people quit is a science project, not a business.

I walk if Retension sells more stock before releasing Phase 2b data, unless an unexpected trial expansion clearly creates more value than the dilution takes. The IPO should fund the answer. Asking shareholders to pay twice before showing it would be a rotten deal.

I also walk if the crystal patent falls into a dispute that threatens ownership, if the royalty rises beyond the disclosed low-teens range, or if management does not repair the financial-control weakness. One drug already supplies enough drama. The paperwork does not need its own season.

IPO Watch

• Iambic Therapeutics, private, proposed ticker IAM, expected October 15 at $15 to $17. It uses artificial intelligence and automated laboratories to design cancer drugs. The range means bankers are testing what buyers will pay. I would write it up if human tumor data supports the software pitch and the final valuation leaves room for failed trials.
• City Therapeutics, private, proposed ticker CTY, expected October 16 at $17 to $19. It develops RNA-interference medicines that silence disease-causing genes. The range is the expected IPO price, not a promise. I would write it up if its lead program shows a clear advantage over existing gene-silencing drugs and the balance sheet can fund meaningful human data.

The verdict

Score: 54 out of 100. Bucket: pass for now. Retension earned points for a huge medical need, a differentiated mechanism, a useful early safety file, cash that should reach the readout, and a decisive catalyst in the first half of 2027.

It lost far more for zero revenue, one drug, undisclosed pilot effect sizes, an old and tiny efficacy study, a delayed trial timetable, fierce competition, a future Phase 3 funding hole, patent and royalty uncertainty, related-party conflicts, weak financial controls, and potential share dilution near 31%. A watch starts at 65. Retension misses by eleven. I do not pay full price for an efficacy result management has not shown me.

The DBTech read

A dose response asks whether more drug produces more effect in a sensible pattern. If 15 milligrams helps a little, 30 helps more, and 45 reaches the best balance before side effects jump, the biology looks believable. If the smallest dose wins and the larger doses wander, chance or trial noise may be driving the result. Good dose response does not guarantee approval, but it gives the next trial a rational dose. In drug investing, a clean staircase beats one lucky step.

Sources and as-of date

• Price: $11.63 at 4:00 p.m. Eastern on October 13, 2026, the latest completed regular-session close, with an $11.83 open, $12.50 high, $11.41 low, and roughly 137,000 shares traded, Exa Markets. Retrieved at 7:06 a.m. Eastern on October 14, 2026. The $11.63 close drives every valuation here. Read-only Robinhood price and option-chain tools were not available in this run, so no contract, fill, bid, ask, or Greek is assumed.
• IPO terms, post-offering shares, cash, losses, research spending, planned use of proceeds, 21-month runway, clinical history, risks, patents, royalties, related parties, controls, options, warrants, and lockup: Retension final prospectus, dated October 8, 2026.
• Trial design, enrollment, doses, sites, status, endpoints, and estimated completion dates: ClinicalTrials.gov NCT07142356, retrieved October 14, 2026. Completion dates are estimates and can move.
• Treatment benchmarks and competing approaches: JACC: Advances 2026 network meta-analysis, retrieved October 14, 2026.
• Independent IPO and trial analysis: The IPO Radar and Renaissance Capital, retrieved October 14, 2026.
• Upcoming IPO dates and ranges: StockAnalysis IPO calendar and MetaCap IPO calendar, updated October 14, 2026. Dates and ranges can change until the deals price.
• Community research covered September 14 through October 14, 2026. It returned 13 Reddit threads and one YouTube video, but only one thread and the small video were company-specific. Hacker News, GitHub, and prediction markets produced no useful company evidence. Raw research: workspace/newsletters/a-portfolio/research/retension-pharmaceuticals-rtsn-rtn-001-raw-v3.md.
• Calculations use decimal arithmetic, the $11.63 close, 8,332,047 current shares, $52.56 million of pro forma cash, and the disclosed options, warrants, and employee-plan reserve. The cash figure starts from June 30 and adds estimated IPO proceeds, so later spending will reduce it. Research and commentary only, never a buy signal.